Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyNeoadjuvant Chemoradiotherapy vs. Neoadjuvant Chemotherapy for Patients with Stage III-N2M0 Non-Small Cell Lung Cancer (NSCLC): A Population-Based Study

The authors investigated the effect of adding radiotherapy to neoadjuvant chemotherapy on survival in patients with Stage III-N2 non-small cell lung cancer. Analysis included 1,175 patients diagnosed between 2004 and 2015; 799 (68.0%) underwent neoadjuvant CRT and 376 (32.0%) underwent neoadjuvant CT. Adding radiotherapy to chemotherapy showed a slightly higher median OS than chemotherapy alone (51 vs. 47 months, respectively), and a higher median CSS (75 vs. 59 months, respectively). However, these differences were not statistically significant.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form